Pharmaceutical-grade cGMP consulting for OTC drug manufacturers. From quality system design to FDA inspection readiness, we build the compliance infrastructure that passes scrutiny.
CPGP-certified expertise in process validation, batch record design, cleaning validation, equipment qualification, and stability testing programs.
The pharmaceutical cGMP regulations that govern every OTC drug manufactured and sold in the United States
If you manufacture OTC drugs — analgesics, antacids, cough and cold medicines, topical antiseptics, sunscreens, or any product classified as a drug by the FDA — your facility must comply with 21 CFR Parts 210 and 211. These are the current Good Manufacturing Practice (cGMP) regulations for finished pharmaceutical products, and they represent the most rigorous manufacturing standards the FDA enforces.
Part 210 establishes the general applicability of cGMP requirements to all drug manufacturing, processing, packing, and holding. Part 211 lays out the specific requirements across eleven subparts covering everything from your organizational structure and buildings to laboratory controls, production records, and returned/salvaged goods. Together, they form a comprehensive framework that touches every aspect of your manufacturing operation.
Many manufacturers — especially those transitioning from dietary supplement or cosmetics production — underestimate the gap between their current quality systems and what pharmaceutical cGMP demands. Supplement manufacturers operating under 21 CFR Part 111 often assume their existing systems will transfer. They do not. The documentation requirements are more granular, the validation expectations are more formal, and the consequences of non-compliance are significantly steeper.
A single FDA Form 483 observation can trigger an enforcement cascade: follow-up inspections, warning letters, import alerts, consent decrees, and in extreme cases, criminal prosecution. The pharmaceutical regulatory environment leaves no room for ambiguity in your quality systems.
General Provisions
Scope, definitions, applicability
Organization & Personnel
Quality unit responsibilities, training, hygiene
Buildings & Facilities
Design, construction, lighting, ventilation, plumbing
Equipment
Design, calibration, cleaning, maintenance logs
Control of Components & Containers
Receipt, identity testing, storage, rejection criteria
Production & Process Controls
Written procedures, batch sizing, in-process controls
Packaging, Holding, Lab Controls, Records & Returns
Labeling, storage, testing, batch records, complaint handling
Comprehensive support across every element of 21 CFR 210 & 211 compliance — from initial gap analysis through successful FDA inspection
We design and implement pharmaceutical-grade quality management systems built specifically for OTC drug manufacturers. This includes establishing your Quality Unit structure with clearly defined responsibilities, developing your CAPA (Corrective and Preventive Action) system, building complaint handling procedures, and creating change control protocols.
Your QMS becomes the backbone of your compliance program — every SOP, every deviation, every decision traces back to a documented, auditable process.
Pharmaceutical batch production records under 211.188 require a level of detail that supplement manufacturers rarely encounter. We design master production records and batch production records that capture every critical parameter: weights, measurements, equipment IDs, in-process test results, environmental conditions, personnel, and time stamps.
Every record is designed to be complete, accurate, and FDA-ready from the moment your operator signs off.
Section 211.166 requires a formal written stability testing program for every drug product. We develop ICH-aligned stability protocols that include long-term, accelerated, and intermediate storage conditions, proper container-closure systems, scientifically justified testing intervals, and statistically valid sample sizes.
Your stability program establishes and supports your product expiration dates with defensible data that withstands FDA scrutiny.
Cross-contamination prevention is a top priority for FDA investigators. We develop cleaning validation protocols that establish scientifically justified acceptance limits, identify worst-case product groupings, define sampling methods (swab and rinse), and specify analytical methods for residue detection.
Each cleaning SOP is validated with three consecutive successful runs and documented to demonstrate your equipment is clean before every production batch.
Every piece of manufacturing equipment must be qualified before use in pharmaceutical production. We execute the full qualification lifecycle: Installation Qualification (IQ) confirms proper installation per manufacturer specs, Operational Qualification (OQ) verifies equipment operates within design parameters, and Performance Qualification (PQ) demonstrates consistent performance under actual production conditions.
We also establish calibration programs and preventive maintenance schedules that keep your qualified status current.
The FDA's 2011 Process Validation Guidance defines a three-stage lifecycle approach: Process Design, Process Qualification, and Continued Process Verification. We implement this framework for every drug product, establishing critical process parameters (CPPs), critical quality attributes (CQAs), and the statistical evidence that your manufacturing process consistently produces product meeting its predetermined specifications.
This is where supplement manufacturers consistently stumble when entering pharmaceutical manufacturing — and where our CPGP expertise makes the difference.
OTC drug cGMP under 21 CFR 210/211 is the most demanding manufacturing standard the FDA enforces. Here is how it compares.
21 CFR 210/211
21 CFR 111
21 CFR 117
If you currently manufacture dietary supplements under 21 CFR 111 and want to add OTC drug products, you cannot simply apply your existing quality system to pharmaceutical production. The gap between Part 111 and Parts 210/211 is substantial. You will need formal process validation, cleaning validation with scientifically justified acceptance limits, ICH-aligned stability programs, full equipment qualification, and significantly more detailed batch production and control records.
We specialize in guiding supplement manufacturers through this transition without disrupting their existing operations. Our FDA inspection preparation ensures you are audit-ready for both product categories.
The Certified Pharmaceutical GMP Professional (CPGP) credential from ASQ is the only professional certification specifically focused on pharmaceutical cGMP expertise. It covers FDA and international regulatory requirements, pharmaceutical quality systems, production and process controls, laboratory operations, and packaging and labeling controls.
When you hire a CPGP-certified consultant, you are working with someone who has demonstrated mastery of the exact regulations that govern your OTC drug manufacturing operation. Combined with Jared Clark's JD, RAC, and CMQ-OE credentials, you get regulatory, legal, and quality expertise in a single engagement. Learn more about GMP credentials.
The FDA publishes Form 483 observations after every inspection. These are the violations we see most frequently — and how we help you prevent them.
The single most cited 483 observation for drug manufacturers. The FDA expects thorough, documented investigations into any unexplained discrepancy or failure of a batch to meet specifications. "We looked into it and it was fine" is not an investigation.
Our approach: We build structured investigation templates with root cause analysis (Ishikawa, 5-Why), impact assessments, corrective action requirements, and effectiveness checks. Every investigation follows a documented, repeatable methodology.
Laboratory testing must follow scientifically sound and appropriate specifications, standards, sampling plans, and test procedures. FDA investigators look for validated analytical methods, proper reference standards, instrument qualification, and data integrity controls.
Our approach: We establish comprehensive laboratory control SOPs, analytical method validation protocols, out-of-specification (OOS) investigation procedures, and data integrity policies aligned with FDA's Data Integrity and Compliance guidance.
Written procedures for production and process control must be followed in the execution of production and process control functions. Any deviation must be recorded and justified. The FDA scrutinizes whether your actual operations match your documented procedures.
Our approach: We write SOPs that reflect how your operation actually works — not theoretical ideals. Then we train your team to execute consistently, document deviations properly, and manage changes through formal change control.
Equipment and utensils must be cleaned, maintained, and sanitized at appropriate intervals to prevent contamination. FDA investigators check cleaning logs, maintenance records, and whether your cleaning procedures have been validated with analytical data.
Our approach: We develop cleaning validation master plans, execute validation protocols with worst-case product groupings, establish hold-time studies, and implement preventive maintenance programs with equipment logbooks that satisfy FDA expectations.
A written testing program must be established to assess the stability characteristics of drug products. Expiration dates must be supported by appropriate stability data. Many OTC manufacturers either lack formal stability programs or have programs that do not meet ICH guidelines.
Our approach: We design ICH Q1A-aligned stability protocols, establish stability-indicating methods, define storage conditions and testing intervals, and create trending and reporting systems that support your product shelf life claims with defensible data.
Any automated, mechanical, or electronic equipment used in production or testing must be validated for its intended use. With increasing use of computerized systems, FDA focuses on computer system validation (CSV), electronic records and signatures (21 CFR Part 11), and audit trail integrity.
Our approach: We perform risk-based CSV assessments, develop User Requirement Specifications, execute IQ/OQ/PQ for computerized systems, and ensure your electronic records comply with 21 CFR Part 11 requirements for data integrity.
Already received a 483 observation? We provide rapid-response 483 remediation consulting to address findings before they escalate to warning letters.
Schedule a free consultation with Jared Clark, CPGP, RAC, JD. We will assess your current state against 21 CFR Parts 210 & 211, identify every gap, and build a clear roadmap to FDA compliance.